Form 4: Syros Pharmaceuticals Executive Kristin Stephens Reports Stock Transactions

Kristin Stephens, Chief Development Officer at Syros Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Kristin Stephens, Chief Development Officer of Syros Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On October 31, 2024, Stephens vested 17,000 restricted stock units, receiving 17,000 shares of common stock.
• Also on October 31, 2024, 6,104 shares were disposed of at a price of $2.09 to cover tax withholding related to the restricted stock unit release.
• Following these transactions, Stephens directly owns 36,133 shares of Syros Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation and doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders and their holdings in the company.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves the issuance and sale of a relatively small number of shares.
• The transaction impacts the executive, Kristin Stephens, by providing vested equity as part of her compensation.

Key Dates

Keywords

Form 4, Beneficial Ownership, Syros Pharmaceuticals, Stock Transaction, Restricted Stock Units, Insider Trading, Executive Compensation, Stephens, SYRS